BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.
Zacks
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers
Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion.
SCYNEXIS (NASDAQ:SCYX) stock increased by 15.7%read more...
Benzinga
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead...
PR Newswire
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully...
PR Newswire
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results PR Newswire NEW HAVEN, Conn., August 10, 2026 First extracellular protein degraders in the clinic demonstrate rapid and...
PR Newswire
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors PR Newswire NEW HAVEN, Conn., Aug. 6, 2026 Infinitum founder and Groq board director brings frontier AI and technology-investing expertise toBiohaven...
PR Newswire
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at...
PR Newswire
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload PR...
PR Newswire
Biohaven Announces Scientific Leadership Transitions
Biohaven Announces Scientific Leadership Transitions Biohaven Announces Scientific Leadership Transitions PR Newswire NEW HAVEN, Conn., July 9, 2026 David Pirman, Ph.D. promoted to Executive Vice President and Head of DiscoveryBruce Car, Ph.D. transitioning from Chief Scientific Officer to new role...
PR Newswire